Reports
Sale
Global HIV Drugs Market Share, Research: By Drug Class: Nucleoside Reverse Transcriptase Inhibitors, Multi-Class Combination Drugs, Protease Inhibitors, HIV Integrase Strand Transfer Inhibitors, Others; By Route of Administration; By Drug Type; By End User; By Distribution Channels; Regional Analysis; Supplier Landscape; 2023-2031
Global HIV Drugs Market Outlook
The HIV drug market size attained a value of USD 32.1 billion in 2022. The market is anticipated to grow at a CAGR of 4.5% during the forecast period of 2023-2031 to attain a value of USD 47.8 billion by 2031.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America accounted for the largest share of the market in 2022. The regional growth can be attributed to the increased number of research and development initiatives for new drug launches, a well-established healthcare system, and the growing adoption of advanced treatment options from HIV infected population. Majority of people with HIV are encountered in low as well as middle-income countries. In 2018, there were 20.6 million people with HIV (57%) in eastern and southern Africa, owing to this, the Middle East and Africa is anticipated to register the highest CAGR over the forecast period.
Properties and Applications
Human Immunodeficiency Virus (HIV) is a virus that causes a chronic and life-threatening disease that can be transferred from one person to another through blood-to-blood and sexual contact. It damages the immune system by destroying CD-4 cells, making the body susceptible to infections and other diseases. The rising prevalence of HIV disease across the world has positively impacted the demand for HIV drugs. These drugs prevent the multiplication of HIV and make the immune system strong enough to resist certain infections, thereby reducing the risk of transmission.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
At present, highly active antiretroviral therapy (HAART) is the most prescribed treatment. It has various combinations of one protease inhibitor and other drugs. These combinations aids in increasing the number of CD4+ cells and decreasing the amount of virus in the blood.
On the basis of drug class, the global HIV drugs market is segmented into:
- Nucleoside Reverse Transcriptase Inhibitors
- Multi-Class Combination Products
- Protease Inhibitors
- HIV Integrase Strand Transfer Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Entry Inhibitors — CCR5 Co-Receptor Antagonist
- Fusion Inhibitors
- Others
Based on the distribution channel, the industry can be segregated into:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
The EMR report looks into the regional markets in the global HIV drugs market like North America, the Asia Pacific, Europe, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Analysis
According to the estimates by the World Health Organization (WHO), 37.9 million people are living with HIV, and nearly 2 million people become newly infected at the end of 2018. The growing population density of HIV infected people has been instrumental in the development and introduction of HIV drugs. Besides, the market is also influenced by the rising government initiatives and campaigns to create awareness amongst people regarding the causes, symptoms, and treatments of HIV. Moreover, the introduction of generic drugs acts is another factor that is contributing to the demand for HIV drugs, as they are cost-effective and chemically identical to branded drugs.
Additionally, many international organizations are providing funds to research institutes funds for R&D activities to develop innovative, affordable, safe, and efficient medicines for effective therapeutic solutions. Owing to the aforementioned factors, the demand for HIV drugs is expected to augment over the forecast period. However, the cost of antiretroviral drugs is relatively high, and patients without healthcare coverage find it extremely difficult to pay, which is likely to restrain the market growth up to some extent, contributing to its negative growth rate. The side effects of these drugs is also preventing the growth of the market with many of the patients giving up the medications due to these harsh side effects, which can include hyperlipidemia, osteopenia, lipodystrophy, and osteoporosis The market is also expected to decline in the forecast period due to the rising awareness about how to prevent the spread of the disease and the upcoming patent expirations.
Competitive Landscape
The report presents a detailed analysis of the following key players in the global HIV drugs market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Boehringer Ingelheim International GmbH
- ViiV Healthcare
- Merck & Co., Inc.
- F. Hoffmann-La Roche Ltd.
- Gilead Sciences, Inc.
- Cipla Inc.
- Johnson & Johnson Services, Inc.
- Others
The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2022 |
| Historical Period | 2016-2022 |
| Forecast Period | 2023-2031 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Route of Administration |
|
| Breakup by Drug Type |
|
| Breakup by End User |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 HIV/AIDS Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 HIV/AIDS Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America HIV Epidemiology (2016-2031)
5.3 Europe HIV Epidemiology (2016-2031)
5.4 Asia-Pacific HIV Epidemiology (2016-2031)
5.5 Latin America HIV Epidemiology (2016-2031)
5.6 Middle East & Africa HIV Epidemiology (2016-2031)
6 Global HIV Drugs Market Overview
6.1 Global HIV Drugs Market Historical Value (2016-2022)
6.2 Global HIV Drugs Market Forecast Value (2023-2031)
7 Global HIV Drugs Market Landscape
7.1 Global HIV Drugs Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global HIV Drugs Product Landscape
7.2.1 Analysis by Drug Type
7.2.2 Analysis by End User
7.2.3 Analysis by Distribution Channel
8 Cost of Treatment
9 Global HIV Drugs Market Dynamics
9.1 Market Drivers and Constraints
9.2 SWOT Analysis
9.3 Porter’s Five Forces Model
9.4 Key Demand Indicators
9.5 Key Price Indicators
9.6 Industry Events, Initiatives, and Trends
9.7 Value Chain Analysis
10 Global HIV Drugs Market Segmentation
10.1 Global HIV Drugs Market by Drug Class
10.1.1 Market Overview
10.1.2 Nucleoside Reverse Transcriptase Inhibitors
10.1.3 Multi-Class Combination Drugs
10.1.4 Protease Inhibitors
10.1.5 HIV Integrase Strand Transfer Inhibitors
10.1.6 Non-Nucleoside Reverse Transcriptase Inhibitors
10.1.7 Entry Inhibitors - CCR5 Co-Receptor Antagonist
10.1.8 Fusion Inhibitors
10.1.9 Others
10.2 Global HIV Drugs Market by Route of Administration
10.2.1 Market Overview
10.2.2 Oral
10.2.2.1 Tablets
10.2.2.2 Capsules
10.2.3 Parenteral
10.2.3.1 Intravascular
10.2.3.2 intramuscular
10.2.3.3 Others
10.3 Global HIV Drugs Market by Drug Type
10.3.1 Market Overview
10.3.2 Branded
10.3.3 Generics
10.4 Global HIV Drugs Market by End User
10.4.1 Market Overview
10.4.2 Hospitals
10.4.3 Clinics
10.4.4 Specialty Centers
10.4.5 Research Institutes
10.4.6 Others
10.5 Global HIV Drugs Market by Distribution Channels
10.5.1 Market Overview
10.5.2 Hospitals Pharmacies
10.5.3 Retail Pharmacies
10.5.4 Online Pharmacies
10.5.5 Others
10.6 Global HIV Drugs Market by Region
10.6.1 Market Overview
10.6.2 North America
10.6.3 Europe
10.6.4 Asia Pacific
10.6.5 Latin America
10.6.6 Middle East and Africa
11 North America HIV Drugs Market
11.1 Market Share by Country
11.2 United States of America
11.3 Canada
12 Europe HIV Drugs Market
12.1 Market Share by Country
12.2 United Kingdom
12.3 Germany
12.4 France
12.5 Italy
12.6 Others
13 Asia Pacific HIV Drugs Market
13.1 Market Share by Country
13.2 China
13.3 Japan
13.4 India
13.5 ASEAN
13.6 Australia
13.7 Others
14 Latin America HIV Drugs Market
14.1 Market Share by Country
14.2 Brazil
14.3 Argentina
14.4 Mexico
14.5 Others
15 Middle East and Africa HIV Drugs Market
15.1 Market Share by Country
15.2 Saudi Arabia
15.3 United Arab Emirates
15.4 Nigeria
15.5 South Africa
15.6 Others
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by Year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Regulatory Framework
21.1 Regulatory Overview
21.1.1 US FDA
21.1.2 EU EMA
21.1.3 INDIA CDSCO
21.1.4 JAPAN PMDA
21.1.5 Others
22 Supplier Landscape
22.1 F. Hoffmann-La Roche Ltd.
22.1.1 Financial Analysis
22.1.2 Product Portfolio
22.1.3 Demographic Reach and Achievements
22.1.4 Mergers and Acquisitions
22.1.5 Certifications
22.2 Bristol-Myers Squibb Company
22.2.1 Financial Analysis
22.2.2 Product Portfolio
22.2.3 Demographic Reach and Achievements
22.2.4 Mergers and Acquisitions
22.2.5 Certifications
22.3 AstraZeneca
22.3.1 Financial Analysis
22.3.2 Product Portfolio
22.3.3 Demographic Reach and Achievements
22.3.4 Mergers and Acquisitions
22.3.5 Certifications
22.4 GSK plc
22.4.1 Financial Analysis
22.4.2 Product Portfolio
22.4.3 Demographic Reach and Achievements
22.4.4 Mergers and Acquisitions
22.4.5 Certifications
22.5 Merck & Co., Inc.
22.5.1 Financial Analysis
22.5.2 Product Portfolio
22.5.3 Demographic Reach and Achievements
22.5.4 Mergers and Acquisitions
22.5.5 Certifications
22.6 Novartis AG
22.6.1 Financial Analysis
22.6.2 Product Portfolio
22.6.3 Demographic Reach and Achievements
22.6.4 Mergers and Acquisitions
22.6.5 Certifications
22.7 Pfizer Inc.
22.7.1 Financial Analysis
22.7.2 Product Portfolio
22.7.3 Demographic Reach and Achievements
22.7.4 Mergers and Acquisitions
22.7.5 Certifications
22.8 Sun Pharmaceutical Industries Ltd
22.8.1 Financial Analysis
22.8.2 Product Portfolio
22.8.3 Demographic Reach and Achievements
22.8.4 Mergers and Acquisitions
22.8.5 Certifications
22.9 Mylan N.V.
22.9.1 Financial Analysis
22.9.2 Product Portfolio
22.9.3 Demographic Reach and Achievements
22.9.4 Mergers and Acquisitions
22.9.5 Certifications
22.10 Sanofi
22.10.1 Financial Analysis
22.10.2 Product Portfolio
22.10.3 Demographic Reach and Achievements
22.10.4 Mergers and Acquisitions
22.10.5 Certifications
22.11 Bayer AG
22.11.1 Financial Analysis
22.11.2 Product Portfolio
22.11.3 Demographic Reach and Achievements
22.11.4 Mergers and Acquisitions
22.11.5 Certifications
22.12 ViiV Healthcare group of companies
22.12.1 Financial Analysis
22.12.2 Product Portfolio
22.12.3 Demographic Reach and Achievements
22.12.4 Mergers and Acquisitions
22.12.5 Certifications
22.13 Genentech, Inc
22.13.1 Financial Analysis
22.13.2 Product Portfolio
22.13.3 Demographic Reach and Achievements
22.13.4 Mergers and Acquisitions
22.13.5 Certifications
23 Global HIV Drugs Market-Distribution Model (Additional Insight)
23.1 Overview
23.2 Potential Distributors
23.3 Key Parameters for Distribution Partner Assessment
24 Key Opinion Leaders (KOL) Insights (Additional Insight)
25 Company Competitiveness Analysis (Additional Insight)
25.1 Very Small Companies
25.2 Small Companies
25.3 Mid-Sized Companies
25.4 Large Companies
25.5 Very Large Companies
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The global HIV drug market was valued at USD 156.7 billion in 2022.
The market is expected to grow at a CAGR of 4.5% from 2023 to 2031 to reach a value of USD 47.8 billion by 2031.
The market growth is being constrained by the high cost of the treatment and the side effects of the drugs, along with the upcoming threat of patent expirations and the growing awareness about how to effectively curb the spread of the disease.
The key market trend informing the HIV drugs market includes the emerging provision of research institutes funds for R&D activities to develop innovative, affordable, safe, and efficient medicines for effective therapeutic solutions.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share in the market.
Nucleoside reverse transcriptase inhibitors are the leading drug class of HIV drugs in the industry.
The distribution channel segment is led by hospital pharmacies.
The major players in the industry are Boehringer Ingelheim International GmbH, ViiV Healthcare, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Cipla Inc., and Johnson & Johnson Services, Inc., among others.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$ 3499
$1999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next UpdateSingle User License
$5999$2999-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited CustomisationPost Sales Analyst Support50% Discount on Next Update
Five User License
$7999$3999-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$9999$5999-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Contact AnalystAny Question? Speak With An Analyst
Request SampleView A Sample
Request CustomisationDid You Miss Anything, Ask Now
Why Expert Market Research?Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER